title: Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.
authors: Department of Medicine, Division of Medical Oncology, University of Colorado Denver, Aurora, CO 80045, USA. Eiko.browning@ucdenver.edu
authors: Eiko Theodora
authors: ET
authors: Browning
authors: Andrew James
authors: AJ
authors: Weickhardt
authors: D Ross
authors: DR
authors: Camidge
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000077548:Anaplastic Lymphoma Kinase; D000077547:Crizotinib; D018450:Disease Progression; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases